NASDAQ:OCRX - Ocera Therapeutics Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$1.79Today's Range$1.79 - $1.7952-Week Range$0.52 - $2.95VolumeN/AAverage Volume1.11 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge. Receive OCRX News and Ratings via Email Sign-up to receive the latest news and ratings for OCRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:OCRX Previous SymbolNASDAQ:TZYM CUSIPN/A CIK1274644 Webwww.ocerainc.com Phone+1-650-4750158Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Ocera Therapeutics (NASDAQ:OCRX) Frequently Asked Questions What is Ocera Therapeutics' stock symbol? Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX." How were Ocera Therapeutics' earnings last quarter? Ocera Therapeutics Inc (NASDAQ:OCRX) issued its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.24). View Ocera Therapeutics' Earnings History. Has Ocera Therapeutics been receiving favorable news coverage? Media coverage about OCRX stock has trended positive on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ocera Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. What other stocks do shareholders of Ocera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocera Therapeutics investors own include Neovasc (NVCN), Biopharmx (BPMX), Heat Biologics (HTBX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), BIOLINERX LTD/S (BLRX), Celsion (CLSN), CytRx (CYTR), Gevo (GEVO) and Molecular Templates (MTEM). Who are Ocera Therapeutics' key executives? Ocera Therapeutics' management team includes the folowing people: Linda S. Grais M.D., President, Chief Executive Officer, Director (Age 61)Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 38)Stan Bukofzer M.D., Chief Medical Officer (Age 59)Steven P. James, Lead Independent Director (Age 57)Willard H. Dere M.D., Director (Age 63)Nina S. Kjellson, Independent Director (Age 40)Anne M. VanLent, Independent Director (Age 68)Eckard Weber M.D., Independent Director (Age 66) What is Ocera Therapeutics' official website? The official website for Ocera Therapeutics is http://www.ocerainc.com. How can I contact Ocera Therapeutics? Ocera Therapeutics' mailing address is 555 Twin Dolphin Dr Ste 615, REDWOOD CITY, CA 94065-2130, United States. The biopharmaceutical company can be reached via phone at +1-650-4750158 or via email at [email protected] MarketBeat Community Rating for Ocera Therapeutics (NASDAQ OCRX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 281 (Vote Outperform)Underperform Votes: 254 (Vote Underperform)Total Votes: 535MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe OCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.